Canagliflozin

Generic Name
Canagliflozin
Brand Names
Invokamet, Invokana
Drug Type
Small Molecule
Chemical Formula
C24H25FO5S
CAS Number
842133-18-0
Unique Ingredient Identifier
6S49DGR869
Background

Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
...

Indication

This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
...

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine
Associated Therapies
-
Clinical Trials
Related News

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

First Posted Date
2014-02-19
Last Posted Date
2019-12-05
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
4401
Registration Number
NCT02065791

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

First Posted Date
2013-09-11
Last Posted Date
2017-03-03
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
171
Registration Number
NCT01939496

A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Canagliflozin
Drug: Dapagliflozin
First Posted Date
2013-06-14
Last Posted Date
2014-03-26
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
60
Registration Number
NCT01877889

A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus

First Posted Date
2011-12-01
Last Posted Date
2014-08-20
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
36
Registration Number
NCT01483781

A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Rifampin
Drug: Canagliflozin
First Posted Date
2011-07-18
Last Posted Date
2013-05-06
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
14
Registration Number
NCT01395927

The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Canagliflozin
First Posted Date
2011-04-28
Last Posted Date
2012-10-02
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
24
Registration Number
NCT01343290

A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Canagliflozin
First Posted Date
2011-01-10
Last Posted Date
2013-04-22
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
28
Registration Number
NCT01273558

A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function

Phase 1
Completed
Conditions
Hepatic Insufficiency
Healthy
Interventions
Drug: Canagliflozin
First Posted Date
2010-08-23
Last Posted Date
2013-05-29
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
24
Registration Number
NCT01186588

A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Canagliflozin
First Posted Date
2010-07-05
Last Posted Date
2014-04-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
9
Registration Number
NCT01157000

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

First Posted Date
2010-04-20
Last Posted Date
2013-07-15
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
344
Registration Number
NCT01106690
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy